先天性极重度感音神经性听力损失儿童的血清Prestin和Ribeye水平
Serum Prestin and Ribeye levels in children with congenital profound sensorineural hearing loss.
文献信息
| PMID | 42966816 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Mahmut Tayyar Kalcioglu |
| 作者单位 | Faculty of Medicine, Department of Otorhinolaryngoloy, Istanbul Medeniyet University, Istanbul, Türkiye, Turkey. |
| 期刊 | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery |
| SCI 分区 | Q1 |
| IF | 2.3 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 耳科 |
中文摘要
目的： 本研究旨在评估双侧先天性极重度感音神经性听力损失（SNHL）儿童的血清Prestin和Ribeye（CtBP2）水平，并探讨其作为耳蜗病理循环生物标志物的潜力。
方法： 在一家三级转诊耳鼻咽喉科中心开展了一项病例对照研究。共纳入153名1-6岁儿童，包括75名双侧先天性极重度SNHL儿童和78名听力正常对照。采用酶联免疫吸附试验（ELISA）检测外周血样本中的血清Prestin和Ribeye浓度。采用受试者工作特征（ROC）分析评估诊断性能，并使用多变量协方差分析（MANCOVA）和逻辑回归分析评估与听力损失状态的关联。
结果： 先天性极重度SNHL儿童的血清Prestin和Ribeye水平显著高于听力正常对照（Prestin中位数：930.70 vs. 414.08 pg/mL，p = 0.001；Ribeye中位数：15.49 vs. 6.26 ng/mL，p < 0.001）。使用MANCOVA同时校正年龄和性别后，整体生物标志物谱仍与听力状态显著相关（Wilks' λ = 0.865，p < 0.001）。在ROC分析中，Ribeye对SNHL的判别性能优于Prestin（曲线下面积[AUC]，0.76 vs. 0.65）。逻辑回归分析显示，血清Ribeye水平每增加1个单位，SNHL的比值增加18%（比值比，1.18）。
结论： 先天性极重度SNHL儿童的血清Prestin和Ribeye水平高于听力正常对照。虽然这两种生物标志物均显示出潜力，但其性能可能尚不足以支持将其用作独立的临床检测。需要进一步开展年龄匹配对照的纵向研究和直接生物学验证，以确定这些循环蛋白是否可补充现有的先天性听力损失听力学评估。
英文摘要
PURPOSE: The aim of this study was to evaluate serum Prestin and Ribeye (CtBP2) levels in children with bilateral congenital profound sensorineural hearing loss (SNHL) and to investigate their potential as circulating biomarkers of cochlear pathology.
METHODS: A case-control study was conducted at a tertiary referral otorhinolaryngology center. A total of 153 children aged 1-6 years were included, comprising 75 children with bilateral congenital profound SNHL and 78 normal-hearing controls. Serum Prestin and Ribeye concentrations were measured in peripheral blood samples using enzyme-linked immunosorbent assay (ELISA). Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis, and associations with hearing loss status were evaluated using multivariate analysis of covariance (MANCOVA) and logistic regression analysis.
RESULTS: Serum Prestin and Ribeye levels were significantly higher in children with congenital profound SNHL than in normal-hearing controls (median Prestin: 930.70 vs. 414.08 pg/mL, p = 0.001; median Ribeye: 15.49 vs. 6.26 ng/mL, p < 0.001). After simultaneous adjustment for age and sex using MANCOVA, the overall biomarker profile remained significantly associated with hearing status (Wilks' λ = 0.865, p < 0.001). In ROC analysis, Ribeye demonstrated greater discriminatory performance for SNHL than Prestin (area under the curve [AUC], 0.76 vs. 0.65). Logistic regression analysis showed that each 1-unit increase in serum Ribeye level was associated with an 18% increase in the odds of SNHL (odds ratio, 1.18).
CONCLUSION: Children with congenital profound SNHL exhibited higher serum levels of Prestin and Ribeye than normal-hearing controls. While both biomarkers showed potential, their performance may not yet be sufficient to support their use as standalone clinical tests. Further longitudinal studies with age-matched controls and direct biological validation are required to determine whether these circulating proteins could complement existing audiological assessments of congenital hearing loss.